Literature DB >> 2138446

Prognosis of Down's syndrome with acute leukaemia.

G A Levitt1, C A Stiller, J M Chessells.   

Abstract

The outcome in children with acute leukaemia with (n = 90) and without Down's syndrome (n = 4377) was compared. Sixty three (70%) of those with Down's syndrome had acute lymphoblastic leukaemia and in comparison with 3664 (84%) controls had similar prognostic features except for a significant excess of the 'common' immunological subtype of acute lymphoblastic leukaemia. The outcome of the children with Down's syndrome was significantly worse with a five year overall actuarial survival of 28% compared with 59% in the control group. It appeared that both suboptimal chemotherapy and a high rate of infective problems contributed to the poor survival. Twenty six children with Down's syndrome had acute myeloblastic leukaemia and were significantly younger and had a higher percentage of the megakaryocytic and erythroid subtypes of acute myeloblastic leukaemia than the 713 controls. The outcome was similar in the two groups. It is concluded that the patients with Down's syndrome who develop acute leukaemia should receive standard protocols without modification, but aggressive supportive care is necessary to improve outcome.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2138446      PMCID: PMC1792207          DOI: 10.1136/adc.65.2.212

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  17 in total

Review 1.  The immune system and susceptibility to infections in Down's syndrome.

Authors:  S Levin
Journal:  Prog Clin Biol Res       Date:  1987

2.  Down's syndrome and acute leukemia: myeloblastic or lymphoblastic? Report of forty-three cases and review of the literature.

Authors:  F Rosner; S L Lee
Journal:  Am J Med       Date:  1972-08       Impact factor: 4.965

3.  Association between megakaryoblastic leukaemia and Down syndrome.

Authors:  D S Lewis
Journal:  Lancet       Date:  1981-09-26       Impact factor: 79.321

4.  Excessive chemotherapy-related myelotoxicity in children with Down syndrome and acute lymphoblastic leukaemia.

Authors:  J Blatt; V Albo; W Prin; S Orlando; M Wollman
Journal:  Lancet       Date:  1986-10-18       Impact factor: 79.321

5.  Cell-mediated cytotoxicity in Down syndrome: impairment of allogeneic mixed lymphocyte reaction, NK and NK-like activities.

Authors:  D Montagna; R Maccario; A G Ugazio; L Nespoli; E Pedroni; P Faggiano; G R Burgio
Journal:  Eur J Pediatr       Date:  1988-10       Impact factor: 3.183

6.  Infection during remission induction in childhood leukaemia.

Authors:  J M Chessells; A D Leiper
Journal:  Arch Dis Child       Date:  1980-02       Impact factor: 3.791

7.  Down syndrome and acute leukemia in children: a 10-year retrospective survey from Childrens Cancer Study Group.

Authors:  L L Robison; M E Nesbit; H N Sather; C Level; N Shahidi; A Kennedy; D Hammond
Journal:  J Pediatr       Date:  1984-08       Impact factor: 4.406

8.  Life expectancy in Down syndrome.

Authors:  P A Baird; A D Sadovnick
Journal:  J Pediatr       Date:  1987-06       Impact factor: 4.406

9.  Serious infections during continuing treatment of acute lymphoblastic leukaemia.

Authors:  J Ninane; J M Chessells
Journal:  Arch Dis Child       Date:  1981-11       Impact factor: 3.791

10.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples.

Authors:  R Peto; M C Pike; P Armitage; N E Breslow; D R Cox; S V Howard; N Mantel; K McPherson; J Peto; P G Smith
Journal:  Br J Cancer       Date:  1977-01       Impact factor: 7.640

View more
  17 in total

1.  Malignancies in Down syndrome.

Authors:  P Kusumakumary; T S Vats; R Ankathil; H R Gattamaneni; M K Nair
Journal:  Indian J Pediatr       Date:  1997 Nov-Dec       Impact factor: 1.967

Review 2.  Acute leukemia in children with Down syndrome.

Authors:  Ana C Xavier; Jeffrey W Taub
Journal:  Haematologica       Date:  2010-07       Impact factor: 9.941

3.  Hematopoietic disorders in Down syndrome.

Authors:  John K Choi
Journal:  Int J Clin Exp Pathol       Date:  2008-01-01

4.  Patterns of care and survival for children with acute lymphoblastic leukaemia diagnosed between 1980 and 1994.

Authors:  C A Stiller; E M Eatock
Journal:  Arch Dis Child       Date:  1999-09       Impact factor: 3.791

5.  Down syndrome childhood acute lymphoblastic leukemia has a unique spectrum of sentinel cytogenetic lesions that influences treatment outcome: a report from the Children's Oncology Group.

Authors:  Kelly W Maloney; William L Carroll; Andrew J Carroll; Meenakshi Devidas; Michael J Borowitz; Paul L Martin; Jeanette Pullen; James A Whitlock; Cheryl L Willman; Naomi J Winick; Bruce M Camitta; Stephen P Hunger
Journal:  Blood       Date:  2010-05-04       Impact factor: 22.113

6.  Supportive care utilization and treatment toxicity in children with Down syndrome and acute lymphoid leukaemia at free-standing paediatric hospitals in the United States.

Authors:  Elizabeth G Salazar; Yimei Li; Brian T Fisher; Susan R Rheingold; Julie Fitzgerald; Alix E Seif; Yuan-Shung Huang; Rochelle Bagatell; Richard Aplenc
Journal:  Br J Haematol       Date:  2016-05-10       Impact factor: 6.998

7.  Remission death in acute lymphoblastic leukaemia: a changing pattern.

Authors:  A Atra; S M Richards; J M Chessells
Journal:  Arch Dis Child       Date:  1993-11       Impact factor: 3.791

8.  Excellent long-term survival of children with Down syndrome and standard-risk ALL: a report from the Children's Oncology Group.

Authors:  Yousif Matloub; Karen R Rabin; Lingyun Ji; Meenakshi Devidas; Johann Hitzler; Xinxin Xu; Bruce C Bostrom; Linda C Stork; Naomi Winick; Julie M Gastier-Foster; Nyla A Heerema; Eileen Stonerock; William L Carroll; Stephen P Hunger; Paul S Gaynon
Journal:  Blood Adv       Date:  2019-06-11

9.  Down's syndrome and acute lymphoblastic leukaemia: clinical features and response to treatment.

Authors:  J M Chessells; G Harrison; S M Richards; C C Bailey; F G Hill; B E Gibson; I M Hann
Journal:  Arch Dis Child       Date:  2001-10       Impact factor: 3.791

10.  Acute myelogenous leukaemia in children under 2 years--experiences of the West German AML studies BFM-78, -83 and -87. AML-BFM Study Group.

Authors:  J Vormoor; J Ritter; U Creutzig; J Boos; P Heyen; W D Ludwig; J Harbott; H Löffler; G Schellong
Journal:  Br J Cancer Suppl       Date:  1992-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.